Recurrent In Situ Melanoma Successfully Treated with Ingenol Mebutate

Mansuy, Marion; Nikkels‐Tassoudji, N.; Arrese, Jorge E.; Rorive, Andrée; Nikkels, Arjen

doi:10.1007/s13555-014-0051-4

Cited by 18 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to its approved use, ingenol mebutate has emerged in the last years as an efficient topical agent for the treatment of Bowen's disease [11] , superficial basal cell carcinoma [12] and molluscum contagiosum [13] . To date, there is only one report on successful treatment of recurrent melanoma in situ with ingenol mebutate (0.015% for 3 days) at 6 months of follow-up [5] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ingenol Mebutate for Lentigo Maligna: A Case Report

Gadaldi

Feldmeyer²,

Yawalkar³

et al. 2016

Dermatology

View full text Add to dashboard Cite

Background: Lentigo maligna (LM) is a melanoma in situ on sun-damaged skin, with a strong predilection to the head and neck area of the elderly. Many therapeutic modalities have been proposed in the treatment of this pathology, including surgery, cryotherapy, radiotherapy and topical imiquimod. Up to date surgical excision remains the treatment of choice with the lowest recurrence rate. Recently, a new topical treatment with ingenol mebutate has been described to be efficacious and well tolerated in the treatment of melanoma in situ. Objective: We sought to demonstrate that ingenol mebutate might be an efficacious and well-tolerated treatment in a patient suffering from LM on an aesthetically challenging location. Methods: Case report. Results: After therapeutic failure with imiquimod 5% cream, a new topical treatment with ingenol mebutate gel 0.015% once daily on 3 consecutive days was initiated. Despite visible inflammation, no macroscopic lesion clearance was observed. While the first follow-up using reflectance confocal microscopy (RCM) performed at 6 weeks after the completion of the therapy showed no signs of LM, the second follow-up examination at 12 weeks using RCM and biopsy confirmed recurrence of the lesion. Conclusion: Ingenol mebutate cannot be considered a standard treatment modality for all types of LM. Further studies are needed to evaluate the prerequisites that can ensure therapeutic success.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Surgical excision employing safety margins (usually micrographically controlled) remains the first-line therapy for this pathology. Recently, a new topical treatment with ingenol mebutate (0.015% gel) has been described to be efficacious and well tolerated in the treatment of melanoma in situ [5] .…”

Section: Introductionmentioning

confidence: 99%

Ingenol Mebutate for Lentigo Maligna: A Case Report

Gadaldi

Feldmeyer²,

Yawalkar³

et al. 2016

Dermatology

View full text Add to dashboard Cite

show abstract

“…In a randomized, vehicle‐controlled, Phase 2a study conducted on 60 patients with superficial BCC, when IM 0.05% was given on two consecutive days a complete lesion clearance rate of 63% was observed 85 days posttreatment. Additionally, IM 0.015% was effective for in situ melanoma in a 91‐year‐old woman who had a melanoma on the cheek . A complete clinical resolution was observed and histology and immunohistology revealed no residual melanoma one month posttreatment.…”

Section: Discussionmentioning

confidence: 89%

Ingenol mebutate gel for the treatment of Bowen's disease: a case report of three patients

Redonnet

Codina

2016

Dermatologic Therapy

View full text Add to dashboard Cite

We report three Bowen's disease (BD) cases treated with ingenol mebutate (IM), a novel topical chemotherapeutic agent approved for the treatment of actinic keratosis (AK) that is available in two doses: 0.015% and 0.05%. Three women diagnosed with BD exhibited a positive response after 2 or 3 day period of IM treatment, depending on lesion location. In the three cases, clinical resolution was observed 4 or 9 weeks posttreatment, and was confirmed with histopathology. Local skin reactions were common the first week after treatment but they resolved spontaneously. In our opinion these cases, along with another case reported in Germany, support the concept of commencing of clinical trials using IM on patients with BD.

show abstract

“…Zidovudine (Humer et al, 2008) TERT 0.98 Trametinib (Kim et al, 2012) MAP kinase 0.98 Regorafenib (Istituto Clinico Humanitas, 2015) BRAF 0.98 Nadroparin (Nagy et al, 2009) MYC 0.97 Vinorelbine (Whitehead et al, 2004) MAP kinase 0.93 Irinotecan (Fiorentini et al, 2009) CDKN2A 0.93 Topotecan (Kraut et al, 1997) CDKN2A 0.93 Phase I Sodium stibogluconate (Naing, 2011) CDKN2A 0.93 Case Study Ingenol Mebutate (Mansuy et al, 2014) PRKCA/BRAF 0.95…”

Section: Statusmentioning

confidence: 99%

Peer Review #1 of "Finding melanoma drugs through a probabilistic knowledge graph (v0.1)"

2017

View full text Add to dashboard Cite

Metastatic cutaneous melanoma is an aggressive skin cancer with some progressionslowing treatments but no known cure. The omics data explosion has created many possible drug candidates, however filtering criteria remain challenging, and systems biology approaches have become fragmented with many disconnected databases. Using drug, protein, and disease interactions, we built an evidence-weighted knowledge graph of integrated interactions. Our knowledge graph-based system, ReDrugS, can be used via an API or web interface, and has generated 25 high quality melanoma drug candidates. We show that probabilistic analysis of systems biology graphs increases drug candidate quality compared to non-probabilistic methods. Four of the 25 candidates are novel therapies, three of which have been tested with other cancers. All other candidates have current or completed clinical trials, or have been studied in in vivo or in vitro. This approach can be used to identify candidate therapies for use in research or personalized medicine.

show abstract

Recurrent In Situ Melanoma Successfully Treated with Ingenol Mebutate

Cited by 18 publications

References 9 publications

Ingenol Mebutate for Lentigo Maligna: A Case Report

Ingenol Mebutate for Lentigo Maligna: A Case Report

Ingenol mebutate gel for the treatment of Bowen's disease: a case report of three patients

Peer Review #1 of "Finding melanoma drugs through a probabilistic knowledge graph (v0.1)"

Contact Info

Product

Resources

About